I'm an MIT trained chemist and left a top-tier biotech hedge fund in 2018 to co-found Balmain Pharma with Hiroaki Suga, a professor at the University of Tokyo and the co-founder of Peptidream, one of the largest and most successful Japanese biotech companies to date. We're developing "selective NTCP inhibitors", discovered in his lab, as potential treatments for HBV and expect to file an IND (to start clinical trials) by YE21/1Q22.